Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile

American Journal of Surgical Pathology

Volumn 31, Issue 2, 2007, Pages 247-254

  Mottolese, Marcella ^a   Orlandi, Giulia ^a   Sperduti, Isabella ^a   Merola, Roberta ^a   Buglioni, Simonetta ^a   Di Benedetto, Anna ^a   Pinnarò, Paola ^a   Perracchio, Letizia ^a   Venturo, Irene ^a   Cognetti, Francesco ^a   Cianciulli, AnnaMaria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Chromosome 11 aneusomy; Cyclin D1; Prognosis

Indexed keywords

CYCLIN D1; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 11; CONTROLLED STUDY; CYCLIN D1 GENE; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SEGMENTAL MASTECTOMY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; ANEUPLOIDY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN D1; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MASTECTOMY, SEGMENTAL; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33846616412     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000213345.63228.8d     Document Type: Article

References (35)

1. Ahnstrom M, Nordenskjold B, Rutqvist LE, et al. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat. 2005;91:145-151.
2. Ambrogi F, Biganzoli E, Querzoli P, et al. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. Clin Cancer Res. 2006;12:781-790.
3. Arnold A, Papanikolau A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215-4224.
4. Bacus SS, Gudkov AV, Esteva FJ, et al. Expression of erb-B receptors and their ligands in breast cancer: implications to biological behaviour and therapeutic response. Breast Dis. 2000; 11:63-75.
5. Barbareschi M, Pelosio P, Caffo O, et al. Cyclin-D1 gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21 immunohistochemical expression. Int J Cancer. 1997;74:171-174.
6. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998;52:1-15.
7. Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994;57:353-361.
8. Borg A, Ferno M, Peterson C. Predicting the future of breast cancer. Nat Med. 2003;9;16-18.
9. Botti C, Pescatore B, Mottolese M, et al. Incidence of chromosomes 1 and 17 aneusomy in breast cancer adjacent tissue: an interphase cytogenetic study. J Am Coll Surg. 2000;190:530.
10. Bucholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9:33-41.
11. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339:1-15.
12. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109-118.
13. Fuqa SA, Schiff R, Parra I, et al. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003;63:2434-2439.
14. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994;54:1812-1817.
15. Greenacre MJ. Theory and Applications of Correspondence Analysis. London: Academic Press; 1984.
16. Hui R, Cornish AL, McClelland RA, et al. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res. 1996;2:923-928.
17. Jirstrom K, Stendahl M, Ryden L, et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 2005;65:8009-8016.
18. Kapranos N, Kounelis S, Karantasis H, et al. Numerical aberrations of chromosomes 1 and 7 by fluorescent in situ hybridization and DNA ploidy analysis in breast cancer. Breast J. 2005;11:448-453.
19. Lebart L, Morineau A, Warwick K. Multivariate Descriptive Statistical Analysis. New York: Wiley; 1984.
20. Mauriac L, Debled M, MacGrogar G. When will more useful predictive factors be ready for use? Breast. 2005;14:617-623.
21. Miyoshi Y, Iwao K, Ikeda N, et al. Acceleration of chromosomal instability of BCRA1-associated hereditary breast cancers by p53 abnormality. Breast J. 2002;8:77-80.
22. Naidu R, Wahab NA, Yadav MM, et al. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep. 2002;9:409-416.
23. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of oestrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997;17:5338-5347.
24. Olivier MA, Langerod P, Carrieri J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12:1157-1167.
25. Peters MG, Vidal Mdel C, Giminez L, et al. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep. 2004;12:1143-1150.
26. Rennstam K, Baldetorp B, Kytola S, et al. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res. 2001; 61:1214-1219.
27. Rennstam K, Ahlsted-Soini M, Baldetorp B, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res. 2003;63: 8861-8868.
28. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene. 1995;159:83-96.
29. Seshadri R, Lee CSL, Hui R, et al. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res. 1996;2:1177-1184.
30. Sobin LH, Witteking CH. TNM Classification of Malignant Tumors, UICC. 6th ed. New York: Wiley-Liss; 2002.
31. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
32. Stange DE, Radlwimmer B, Schubert F, et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res. 2006;12:345-352.
33. Tsukamoto F, Miyoshi Y, Egawa C, et al. Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer (Cytopathol). 2001; 93:165-170.
34. Utsumi T, Yoshimura N, Maruta M, et al. Correlation of cyclin D1 mRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. Int J Cancer. 2000;89: 39-43.
35. Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993;71:3926-3931.